Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

- PMLiVE

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

Lilly appoints Philip Johnson to senior VP and treasurer

He currently serves as VP, investor relations at the pharma company

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

Roche Basel Switzerland

New data could unlock bigger market for Roche’s Hemlibra

Trial shows it ‘significantly’ reduced bleeds in some haemophilia A patients

Roche acquires US laboratory big data company Viewics

Gains cloud-based laboratory business analytics capabilities

Roche Basel Switzerland

Roche gets first approval for haemophilia A therapy

The first-in-class therapy wins US marketing licence three months earlier than expected

Roche Basel Switzerland

Roche gets FDA OKs for Alecensa and Zelboraf

Gains US licences for first-line use in lung cancer and a rare blood cancer

Roche Basel Switzerland

Smartphone monitoring shows its worth in Roche MS trial

The tool uses smartphone sensors to measure neurological tests

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links